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Antitumor photodynamic therapy (PDT) comprises 
systemic administration of a photosensitizer and 
subsequent visible light delivery to the tumor lesion. 
Sufficient oxygenation of targeted tissue enables 
photochemical reactions with generation of reactive 
oxygen species and/or free radicals leading to oxida-
tive damage and destruction of sensitized cells [1]. 
Promising clinical results obtained with photodynamic 
therapy stimulate searching of novel photosensitiz-
ers with better chemophysical properties. One of 
such promising substances is hypericin, a natural 
product which was found together with other naph-
thodianthrone derivatives such as pseudohypericin, 
protohypericin, protopseudohypericin, in a number 
of plants of the genus Hypericum, H.perforatum and 
H.maculatum for instance [2].
Nowadays drugs based on Hypericum extract is 
widely used for the treatment of mild and moderate 
depression [3], although there is some evidence that 
indicates that not hypericin but hyperforin is respon-
sible for the antidepressant activity. Also because of 
antiviral activity of hypericin [4] its possible application 
as photodependent blood sterilizer was investigated 
[5]. Hypericin is under investigation as photoinhibitor 
of the progression of proliferative vitreoretinopathy in 
ophthalmology [6].
Due to comparatively high singlet oxygen and su-
peroxide anions generation rate, triplet quantum yield, 
potent light-dependent antineoplastic and antiviral 
activities hypericin is under investigation as a photosen-
sitizer for PDT treatment of superficial bladder tumor 
[7], recurrent mesothelioma, basal and squamous cell 
carcinoma [8] and for inhibition of the growth of malig-
nant glioma [9, 10], pituitary adenoma, and cutaneous 
T-cell lymphoma. Moreover, hypericin is successfully 
applied as a diagnostic tool for the fluorescent detection 
of flat neoplastic lesions in bladder [8, 11, 12].
Hypericin is soluble in polar solvents such as 
ethanol, methanol, acetonitrile, tetrahydrofuran, cy-
clohexane, acetone, dimethylsulfoxide and insoluble 
in nonpolar solvents [13]. At physiological pH hypericin 
forms organic and inorganic monobasic salts in organic 
solvents. Dissolved in organic solvents sodium hyperici-
nate exhibits bright red fluorescence (absorption λmax = 
592 nm, emission λmax = 594 nm in ethanolic solutions) 
[14, 15]. Unfortunately hypericin is insoluble in water 
under physiological conditions and becomes barely 
soluble in pure water if pH rises above 8 [13]. But hyperi-
cin can be solubilized in biological media, if formation 
of complexes with biomacromolecules is possible [14].
Nanoparticles being from several dozens to 
hundreds nanometers in size and from about one 
hundred to ten thousand times smaller than human 
cells, possess unique abilities in interaction with bio-
molecules, what may be used to improve anticancer 
drugs and diagnostic agents. Among the most studied 
nanoparticles are colloid gold, quantum dots, carbon 
nanotubes, silicon and paramagnetic nanoparticles 
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[16, 17]. Main fields of gold nanoparticles application 
in biomedicine are drug delivery, photothermal and 
photodynamic therapy, diagnostics.
MATERIALS AND METHODS
Cell lines. In our studies we used MT-4 and Jurkat 
T-cell leukemic lines and B-cell Burkitt lymphoma cell 
line Namalwa obtained from the Bank of Cell Lines from 
Human and Animal Tissue NAS of Ukraine. Cells were 
cultured in RPMI-1640 medium (FarmBiotek, Ukraine) 
supplemented with 10% fetal cow serum (Sigma, 
Germany) at 37 °C in presence of 5% CO2. Cells were 
reseeded three times a week.
Hyperflav preparations. Hyperflav was provided 
by SIC “Borshchahivskiy Chemical-Pharmaceutical 
Plant”. Hyperflav dried powder was dissolved in 0.9% 
sodium chloride with addition of various concentra-
tions (0.5; 1.25; 2.5; 5 and 10%) of polyvinylpyrrol-
idone and then diluted with sodium chloride to final 
concentration of 500 μg/ml. Hyperflav solutions were 
prepared ex tempore for every experiment.
Nanocomposite Hyperflav-colloid gold was pre-
pared in Scientific Research Institute of Nanotech-
nological Industry by conjugation of commercial of 
commercial Hyperflav with gold nanoparticles. Dried 
substance was dissolved in 0.9% sodium chloride with 
2.5% polyvinylpyrrolidone and further diluted with so-
dium chloride to obtain the concentration of 500 μg/ml.
K-30 polyvinylpyrrolidone (BASF, China) with ap-
proximate molecular weight of 40 kDa was used to 
prepare Hyperflav solutions.
Fluorescence measurements. Fluorescence 
emission spectra of Hyperflav solutions were recorded 
with ND-3300 cuvetteless spectrofluorometr (Nano-
drop Technologies, USA) connected to PC. Measure-
ments were conducted in 1 mm fluid column formed be-
tween surfaces of pedestal and receiving optical fiber.
Radiation sources. As the light source for irradia-
tion of cell samples we used an experimental device 
(Photonika Plus, Ukraine) based on incandescent lamp 
(Philips, USA) equipped with appropriate broadband 
filter. The device emitted light in spectral range of 
560–700 nm. Light beam was delivered to test tubes 
with cells by a fiber-optical probe.
Photodynamic procedure. Each experimental 
sample contained 2 ml of 2 x 106 cells/ml suspension. 
Cell samples were preincubated in Hanks solution 
with addition of appropriate Hyperflav preparations in 
sodium cloride for 1 hour and then washed once to re-
move non-absorbed photosensitizer. After subsequent 
resuspending in Hanks solution, samples were irradi-
ated with a power density of 150 mW/cm2 and a dose 
of 15 J/cm2. Irradiation dose was controlled with the 
help of energy and power meter (3A-p thermal head, 
Ophir Optronics, USA). Irradiated cells were incubated 
in RPMI-1640 media for 24 h, and then a phototoxic 
effect was assessed by trypan blue dye exclusion test.
Statistical analysis. Per cent values of dead cells 
was determined by counting of 200 cells five times for 
each sample, and were presented as a mean ± stan-
dard deviation. One-way ANOVA analysis was used to 
determine significance of difference between means.
RESULTS AND DISCUSSION
The first part of the study was devoted to elabora-
tion of the preparation dissolved forms which would be 
suitable for biological investigations. Several reports 
on photodynamic properties of Hypericum extracts 
have been published earlier [18, 19]. Hyperflav, that is 
actually a dried St. Johns wort (H. perforatum) extract, 
proposed as a photodiagnostic agent, contains about 
2% of hypericin and pseudohypericin. Hyperflav like 
other similar extracts and pure hypericin, is insoluble 
in water, being well soluble in ethanol and other polar 
solvents. It is known that hypericin in aqueous buffers 
is present in a form of colloidal high molecular weight 
aggregates. In such aggregated form hypericin loses 
its photodynamic activity as well as suffers decrease in 
fluorescence yield [14]. Due to its lipophilic properties 
it is possible to prevent aggregation of hypericin by ad-
dition of albumin and plasma lipoproteins that adsorb 
hypericin in aqueous environment [14]. Some macro-
molecular substances such as polyethyleneglycol [14], 
N-methylpyrrolidone [20] and polyvinylpyrrolidone [21, 
22] can be used instead of serum proteins to solubilize 
hypericin in aqueous media.
Thus, to obtain aqueous solutions of Hyperflav for 
cell tests, we used polyvinylpyrrolidone (PVP). A cor-
relation exists between the amount of nonaggregated 
hypericin and its fluorescence yield in a solution [14]. 
Fluorescence emission profile of Hyperflav solubilied in 
water with PVP is almost similar (except its much lower 
intensity) to that in ethanol and specifies hypericin as 
the major photoactive constituent (Fig. 1). Results of 
fluorescent spectroscopy measurements show signifi-
cant decrease in fluorescence intensity of water-PVP 
solubilized Hyperflav compared to ethanolic solution. 
Nevertheless they show presence of some nonaggre-
gated, thus bioavailable and photodynamically active 
hypericin in solution.
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Fig. 1. Fluorescence emission spectra of ethanolic and polyvi-
nylpyrrolidone-aqueous Hyperflav solutions. Concentration of 
Hyperflav 500 μg/ml. Peak fluorescence emission at 597 nm in 
ethanolic solution, and 604 nm in water-PVP solution
In the next stage of the study cytotoxicity cell tests 
were performed to determine influence of Hyperflav to 
PVP ratio on photodynamic activity of solutions (Fig. 2). 
Samples containing Hyperflav in concentration of 10 μg/
ml with 20, 50, 100, 200 or 400 μg/ml of PVP in 0.9% 
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sodium chloride were tested. Maximal activity under 
light irradiation was shown by the solution with 1:5 ratio 
(10 μg/ml Hyperflav and 50 μg/ml PVP). No statistically 
significant cytotoxicity in dark conditions was observed.
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Fig. 2. Photodynamic treatment of Jurkat cells. Hyperflav-
polyvinylpyrrolidone (w/w) ratios 1:2, 1:5, 1:10, 1:20 and 1:40. 
*Significantly different from control at p < 0.05
Next, using the most effective Hyperflav: polyvi-
nylpyrrolidone ratio 1:5, we assessed photodynamic 
activity of Hyperflav on three different cell cultures. 
Under light irradiation Hyperflav showed dose de-
pendent cytotoxicity. Data obtained in tests with 
Jurkat, Namalwa and MT-4 cell lines are presented 
in Fig. 3–5. As it follows from the figures, 69.9, 78.3 
and 76% cell death was observed in respective culture 
samples preincubated with Hyperflav in concentration 
of 15 μg/ml, and the preparation in concentration of 
20–25 μg/ml was able to induce near total death of 
tested cells. No significant cytotoxicity was observed 
in dark conditions.
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Fig. 3. Photodynamic treatment of Jurkat cells with Hyperflav 
in different concentrations. *Significantly different from control 
at p < 0.05
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Fig. 4. Photodynamic treatment of MT-4 cells with Hyperflav 
in different concentrations. *Significantly different from control 
at p < 0.05
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Fig. 5. Photodynamic treatment of Namalwa cells with Hyperflav 
in different concentrations. *Significantly different from control 
at p < 0.05
Among different nanotechnology products gold 
nanoparticles draw a special attention as perspective 
drug delivery agents for cancer therapy [16, 17, 23]. 
Similar to the Hyperflav solubility problem, nanopar-
ticles can be stabilized in colloidal state by biocompa-
tible polymers which are able to inhibit colloid aggrega-
tion in physiological conditions [16].
Therefore a conjugated preparation of Hyperflav 
with nanogold, stabilized by PVP, was obtained and 
preliminarily tested using Namalwa cell culture. Con-
trary to expectations phototoxic tests revealed de-
crease in phototoxicity of nanocomposite preparation 
in comparison with Hyperflav alone (Fig. 6).
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Fig. 6. Effect of photodynamic treatment with Hyperflav and 
Hyperflav-nanogold on Namalwa cells. *Significantly different 
from control at p < 0.05
The preliminary results obtained may be explained 
by the fact that Hyperflav is polycomponent substance 
containing not only the prooxidant constituent (hyperi-
cin) but antioxidative ones (flavonoids, quercetin) as 
well [24]. It could interfere with the cell oxidative da-
mage by PDT. Also, the influence of gold nanoparticles 
on bioavailability and distribution of prooxidative and 
antioxidative components of the preparation in cell 
culture system is still to be studied.
CONCLUSION
Hyperflav can be maintained in aqueous solution 
in presence of polyvinylpyrrolidone. Hyperflav in dose 
of 15 μg/ml shows photodynamic activity in tests with 
leukemic cell cultures Jurkat, Namalwa and MT-4, 
inducing approximately 70% cell death and does not 
show dark toxicity. Conjugation with gold nanoparticles 
causes decrease in phototoxic activity of Hyperflav.
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